Regeneron Earnings: Is Now the Time to Buy?

Regeneron’s Eylea sales slowed down slightly during the first quarter, although the company beat estimates on both the top and bottom lines.

May 12, 2014 at 3:25PM

Regeneron (NASDAQ:REGN) reported its first-quarter earnings on May 8, topping analyst expectations on both the top and bottom lines. Regeneron's non-GAAP diluted earnings rose 27% year over year to $2.26 per share, or $263 million, topping the Thomson Reuters consensus estimate of $2.20 per share.

Regeneron's revenue rose 42% to $626 million, topping the consensus estimate of $609 million. However, U.S. sales of the eye treatment Eylea, the company's main source of revenue, rose 14% to $359 million, missing analyst estimates of $404 million.

REGN Chart

Regeneron attributed the slowdown in Eylea sales to a decrease in distributor inventory and a harsh winter in the U.S., which kept more patients at home. Regeneron's partner Bayer (NASDAQOTH:BAYRY) markets Eylea outside the United States, where it reported sales of $218 million -- a 252% jump from the prior year quarter. Regeneron received $61 million from its share of Eylea profits outside the United States during the quarter. Regeneron finished the quarter with $1.18 billion in cash -- a 9% increase from the prior year quarter.

Overall, Regeneron delivered robust earnings and revenue growth, but the stock fell nearly 2% after earnings. However, let's take a look at why Regeneron is still a solid investment at current prices.

The slump in Eylea sales will only be temporary
Investors shouldn't be concerned about weaker-than-expected sales of Eylea. Regeneron reaffirmed its forecast for $1.7 billion in $1.8 billion in U.S. Eylea sales by the end of the year -- which would signify a healthy 21% to 28% increase from 2013 sales. Last year, Eylea generated $1.88 billion in sales worldwide. Analysts at UBS believe sales could go much higher, hitting peak sales of $3.7 billion by 2020.

However, Eylea needs to be approved for several additional indications before it can hit those peak estimates. Eylea lags behind its primary competitor, Novartis (NYSE:NVS) and Roche's (NASDAQOTH:RHHBY) Lucentis, in terms of total approved indications:




Wet Age-related macular degeneration (AMD)

approved (U.S. and Europe)

approved (U.S. and Europe)

Diabetic macular edema (DME)

Phase 3, BLA submitted

approved (U.S. and Europe)

Macular edema following central retinal vein occlusion (CRVO)

approved (U.S. and Europe)

approved (U.S. and Europe)

Macular Edema following branch retinal vein occlusion (BRVO)

Phase 3, BLA submitted

approved (U.S. and Europe)

Choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV)

Phase 3

approved (Europe)

Source: Company websites, press releases.

Of these indications, the most important one is diabetic macular edema, or DME. DME affects approximately 8% of diabetics within the first five years of the disease, with 42% eventually developing the condition later in their lives. The FDA will reach a decision regarding the supplemental BLA (biologics license application) for Eylea's DME indication on August 18, which could be a positive catalyst for the stock.

Investors should also note that Roche's Avastin has been gaining acceptance as an off-label treatment for both Wet AMD, DME, and other eye conditions. The reason is the price -- Avastin can cost as little as $50 per injection, much less than Lucentis and Eylea, which both cost up to $2,000 per dose.

A trio of potential blockbusters
Looking beyond Eylea, however, Regeneron is also developing a trio of potential blockbusters in its pipeline with Sanofi (NYSE:SNY). These three fully human monoclonal antibodies -- alirocumab, sarilumab, and dupilumab, are the keys to beefing up Regeneron's long-term portfolio:


Potential Indication


Peak Sales Estimate


lower "bad" LDL cholesterol

Phase 3

$3.5 billion (Goldman Sachs)


rheumatoid arthritis

Phase 3

$3.1 billion(SG Cross)


allergic diseases

Phase 2b

$2.8 billion (Leerink Swann)

Sources: Company and industry websites.

Alirocumab is a similar treatment to Amgen's AMG 145 (evolocumab) and Pfizer's RN-316. All three treatments target PCSK9, an enzyme which binds to the liver's LDL receptors and degrades their ability to lower LDL cholesterol levels. AMG-145 and RN-316 are currently in phase 3 trials as well.

Meanwhile, Sarilumab targets a very lucrative market -- rheumatoid arthritis treatments, such as Johnson & Johnson and Merck's Remicade, Amgen's Enbrel, and AbbVie's Humira are among the top-selling drugs in the world.

The Foolish takeaway
In conclusion, investors shouldn't fret about the temporary lull in Eylea sales. Eylea still has lots of room to grow, and an additional approval for DME could help keep the pressure on Lucentis. Long-term investors should focus on the development of Regeneron and Sanofi's three potential blockbusters -- which could grow into exciting new pillars of growth for both companies.

Six stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers